Danaher Corporation $DHR Shares Sold by Waverly Advisors LLC

Waverly Advisors LLC trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 31.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,265 shares of the conglomerate’s stock after selling 27,240 shares during the quarter. Waverly Advisors LLC’s holdings in Danaher were worth $11,479,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Main Street Group LTD purchased a new position in Danaher during the first quarter worth approximately $25,000. N.E.W. Advisory Services LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth approximately $25,000. WFA of San Diego LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $26,000. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Danaher during the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DHR. Wells Fargo & Company dropped their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Stifel Nicolaus cut their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. HSBC decreased their price target on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Wolfe Research downgraded Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Price Performance

Shares of NYSE DHR opened at $205.06 on Thursday. The firm has a 50-day simple moving average of $202.55 and a 200-day simple moving average of $192.08. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $144.15 billion, a price-to-earnings ratio of 36.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.78. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the business posted $0.77 earnings per share. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

About Danaher

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.